Sign inJoin waitlistJoin the waitlist

Larry Markham

Division Chief and Director of Clinical Research · Indiana University School of Medicine

Credentials: · · · · · ·

History

Clinical Research Division · Indiana University School of Medicine
Present
Pediatric Heart Institute Center · Vanderbilt University Medical Center
Present

Cincinnati Children's Hospital Medical Center
2002–2004
Cardiovascular Disease
1999–2002
University of Arkansas for Medical Sciences
1999–2000
Pediatric Cardiology
1996–1999
Internal Medicine
1996–1999
East Tennessee State Univ, James H Quillen Coll of Med
1992–1996

Research

Atenolol versus losartan in children and young adults with Marfan's syndrome
New England Journal of Medicine · 2014 · 379 citations
Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy
Circulation · 2015 · 251 citations
Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association
Circulation · 2017 · 224 citations

Jonathan Soslow
36 papers
William Burnette
18 papers
Linda Cripe
15 papers
Kan Hor
13 papers
Frank Raucci
11 papers · 2 as a fellow
Christopher Spurney
9 papers
Conner Earl
8 papers · 2 as a resident
David Parra
8 papers
Douglas Sawyer
7 papers
DB
D Benson
6 papers
Jaclyn Tamaroff
6 papers
Katheryn Gambetta
6 papers

Grants

Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
National Heart, Lung, and Blood Institute · R01
PI · $2.3M · Vanderbilt University Medical Center
2024–2028
CHERISH (duCHennE caRdiomyopathy mItigation Sglt2 inHibitor)
National Heart, Lung, and Blood Institute · R61
Contact PI · $966.2K · Vanderbilt University Medical Center
2025–2027

Clinical trials

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
Principal investigator · Recruiting · Phase 1
Vanderbilt University Medical Center
2026–2028
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Principal investigator · Completed · Phase 2
Cumberland Pharmaceuticals
2020–2026